Clinical trials: Age-Related Maculopathy
Macular Degeneration, Age-related Macular Degeneration
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
Long-term observational study to assess the safety, efficacy and quality of life of patients with neovascular age-related macular degeneration (AMD) under Macugen treatment.
- Conditions
- Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration
- Trial name
- MACULA (NCT01245387)
- Testing
- Pegaptanib
- Volunteers
- 1,001 people
- Sponsor
- Pfizer
Geographic Atrophy, Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study, and not due to any safety…
- Trial name
- NCT01527500
- Testing
- LFG316, LFG316 Lower dose
- Where
- 19 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Age-Related Maculopathies
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).
- Conditions
- Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related
- Trial name
- NCT01024998
- Testing
- AAV2-sFLT01
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genzyme, a Sanofi Company
Age-Related Macular Degeneration
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or…
- Trial name
- NCT00134667
- Testing
- Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium)
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Eyetech Pharmaceuticals
Neovascular Age-Related Macular Degeneration
A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration
This is a multicenter, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients with AMD.
- Trial name
- NCT03021785
- Testing
- TK001
- Where
- 5 sites in China
- Volunteers
- 36 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Exudative Age-related Macular Degeneration
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination…
- Trial name
- TOFU (NCT04200248)
- Testing
- RBM-007 Injectable Solution, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 94 people
- Sponsor
- Ribomic USA Inc
Glaucoma, Age Related Macular Degeneration
Assessment of Visual Function With a Portable Brain-computer Interface
1. The purpose of this study is to evaluate the nGoggle's accuracy and repeatability in detecting visual function loss. In addition, the ability to stage glaucomatous damage and investigate the relationship between nGoggle…
- Conditions
- Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
- Trial name
- NCT03760055
- Testing
- nGoggle
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- NGoggle
Geographic Atrophy
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96…
- Trial name
- NCT02745119
- Testing
- Lampalizumab
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 994 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy, Macular Degeneration
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
- Trial name
- NCT04435366
- Testing
- Avacincaptad Pegol
- Where
- 205 sites in United States, Argentina and 18 more
- Volunteers
- 448 people
- Sponsor
- IVERIC bio, Inc.
Age Related Macular Degeneration
Usability of the PreView PHP for Home Use in Intermediate AMD Patients
To demonstrate the ability of intermediate AMD subjects to follow the instructions for use and properly operate on their own the Preview PHP in home use environment, after going through training session.
- Trial name
- NCT00776451
- Where
- Israel
- Volunteers
- 66 people
- Sponsor
- Notal Vision Ltd.
Geographic Atrophy
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
- Trial name
- AiiM OLE (NCT07807969)
- Testing
- Vonaprument
- Where
- 7 sites in United States
- Volunteers
- 605 people
- Sponsor
- Annexon, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- ARTEMIS (NCT06856577)
- Testing
- Ixo-vec, Aflibercept
- Where
- 75 sites in United States
- Volunteers
- 311 people
- Sponsor
- Adverum Biotechnologies, Inc.
Retinitis Pigmentosa, Choroideremia
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease
- Trial name
- NCT06375239
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Ray Therapeutics, Inc.
Neovascular (Wet) Age-related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
- Trial name
- PACIFIC (NCT04847895)
- Testing
- Lucentis
- Where
- 175 sites in Germany, Netherlands and 1 more
- Volunteers
- 5,500 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
The FORESEE HOME is used in the recent years to detect Age-related Macular Degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT00884637
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration (wAMD)
Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
This Phase I/IIa study is designed to evaluate the safety, tolerability, preliminary pharmacodynamics and pharmacokinetics in patients with wet age-related macular degeneration.
- Trial name
- NCT06707753
- Testing
- AL-001
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
Dry Age Related Macular Degeneration
A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD
To evaluate the safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry AMD To evaluate the safety of the surgical procedures when used to implant MA09-hRPE cells To assess the number of hRPE cells to…
- Trial name
- NCT01674829
- Testing
- MA09-hRPE
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- CHABiotech CO., Ltd